tradingkey.logo

CVS Health Helps Customers Accelerate Biosimilar Adoption Through Formulary Changes For Affordable Osteoporosis Care

ReutersFeb 5, 2026 1:27 PM

- CVS Health Corp CVS.N:

  • CVS HEALTH HELPS CUSTOMERS ACCELERATE BIOSIMILAR ADOPTION THROUGH FORMULARY CHANGES - SUPPORTING AFFORDABLE OPTIONS FOR OSTEOPOROSIS CARE

  • CVS HEALTH CORP: EFFECTIVE APRIL 1, 2026, CVS CAREMARK WILL BEGIN OFFERING OSTEOPOROSIS BIOSIMILARS OSPOMYV AND STOBOCLO

  • CVS HEALTH CORP: EFFECTIVE APRIL 1, 2026, CVS CAREMARK WILL ALSO BEGIN OFFERING GENERIC TERIPARATIDE, BONSITY, AND TYMLOS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI